Gensight Biologics (XPAR:SIGHT) Total Liabilities : €39.80 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Total Liabilities?

Gensight Biologics's Total Liabilities for the quarter that ended in Dec. 2023 was €39.80 Mil.

Gensight Biologics's quarterly Total Liabilities increased from Dec. 2022 (€41.29 Mil) to Jun. 2023 (€43.80 Mil) but then declined from Jun. 2023 (€43.80 Mil) to Dec. 2023 (€39.80 Mil).

Gensight Biologics's annual Total Liabilities increased from Dec. 2021 (€40.66 Mil) to Dec. 2022 (€41.29 Mil) but then declined from Dec. 2022 (€41.29 Mil) to Dec. 2023 (€39.80 Mil).

Gensight Biologics Total Liabilities Historical Data

The historical data trend for Gensight Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Total Liabilities Chart

Gensight Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

21.97

35.61

40.66

41.29

39.80

Gensight Biologics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															40.66	37.32	41.29	43.80	39.80

Gensight Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Gensight Biologics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	25.29	+	(1.048	+	12.204
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	1.258)
	=	39.80

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	9.132	-	-30.668
	=	39.80

Gensight Biologics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	25.29	+	(1.048	+	12.204
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	1.258)
	=	39.80

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	9.132	-	-30.668
	=	39.80

Gensight Biologics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics (XPAR:SIGHT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (XPAR:SIGHT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GSGTF:USA G49N:Germany

Address

74,rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics (XPAR:SIGHT) Headlines

No Headlines